Mission Statement
Enhancing detection across a variety of applications
The Problem
Non-alcoholic fatty liver disease (NAFLD) affects 30% of the U.S population. Caused by excessive accumulation of fat in a person’s liver, NAFLD is asymptomatic in its earliest stages and challenging to detect.
The Problem
The Solution
The Solution
Arrow Dx is developing highly sensitive detection chips that can be incorporated into portable sensors.
The Solution
The Solution
Arrow Dx is developing highly sensitive detection chips that can be incorporated into portable sensors.
Our Technology
Our proprietary technology allows for an enhanced detection method necessary for the early diagnosis of many diseases such as COVID-19, E.coli, and NAFLD such that an effective treatment can be found thus making it easier for both the patient and physician.
Our technology is the key to unlocking fast, reliable, and flexible diagnostics for a wide variety of applications ranging from early-stage disease detection to environmental pollutant detection to quality control in the wine industry.
Interview of Dr. Sanjiv Chopra
Department of Medicine, at Beth Israel Deaconess Medical Center
Scientific Advisory Board
- Sanjiv Chopra, M.B.B.S., M.A.C.P., Harvard Medical School & James Tullis Firm Chief, Department of Medicine, at Beth Israel Deaconess Medical Center
- David E. Cohen MD-PhD., Chief of Division of Gastroenterology & Endoscopy at Brigham and Women’s Hospital, Harvard Medical School
- David P. Nunes, MD, Director of Hepatology, Assoc. Professor of Medicine, Boston Univ. School of Medicine
- Joe DiStefano III, Ph.D., Distinguished Professor of Computer Science and Medicine, University of California, Los Angeles
Board of Advisors
- PAUL HAYRE, MBA, Executive Director at Harvard Grid, Executive Director at Harvard Grid, Co-Founder Sano Dx, Board Member Monarch Health
